LONGDA(SZ:002726)2023-10-19 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 3,379,692,637, a decrease of 27.11% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 24,167,172, representing a significant decline of 284.33% year-on-year[5]. - The company reported a basic earnings per share of -0.0224 for Q3 2023, a decrease of 285.12% year-on-year[5]. - The net profit for the period was a loss of ¥698,305,622.33, compared to a profit of ¥94,115,990.01 in the previous year, indicating a significant decline[20]. - The company reported a basic earnings per share of -0.6009, compared to 0.0500 in the same period last year[21]. Cash Flow - The net cash flow from operating activities decreased by 1,424,032,624.95, a reduction of 159.14% compared to the previous year[11]. - The net cash flow from operating activities for Q3 2023 was -529.18 million, compared to 894.85 million in the same period last year[23]. - The net cash flow from investing activities was 297.10 million, a significant improvement from -476.78 million in Q3 2022[23]. - The net cash flow from financing activities was 315.47 million, compared to -724.22 million in the previous year[23]. - The cash inflow from financing activities totaled 2.62 billion, an increase from 1.80 billion in Q3 2022[23]. - The cash outflow for financing activities was 2.30 billion, compared to 2.53 billion in the same quarter last year[23]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,277,729,577.33, down 8.77% from the end of the previous year[5]. - Current assets totaled RMB 3,839,860,815.01, down from RMB 4,465,667,354.85 at the start of the year, indicating a decline of approximately 14.0%[16]. - Cash and cash equivalents decreased to RMB 1,364,874,000.27 from RMB 1,855,921,035.70, representing a decline of about 26.5%[15]. - The company's total liabilities increased to ¥4,676,856,131.33 from ¥4,473,404,779.94, reflecting a rise of 4.5%[20]. - The total equity attributable to shareholders decreased by 23.84% to CNY 2,528,698,813.33 compared to the previous year[5]. Shareholder Information - The company reported a total of 35,055 common stock shareholders at the end of the reporting period[13]. - The largest shareholder, Blue Run Development Holdings Group, holds 27.23% of shares, amounting to 293,885,800 shares, with 87,870,000 shares pledged[13]. - The company has a repurchase account holding 20,836,983 shares, representing 1.93% of total shares[14]. - The top ten shareholders collectively hold a significant portion of the company's equity, with the top three alone accounting for over 40%[13]. Operating Costs and Expenses - Total operating costs amounted to ¥10,459,170,677.73, down 8.2% from ¥11,393,918,928.42 year-on-year[19]. - The financial expenses increased by 15,019,310.79, an increase of 38.69% compared to the same period last year, primarily due to reduced interest income[9]. - The company experienced a significant increase in financial expenses, which rose to ¥53,841,048.19 from ¥38,821,737.40, reflecting higher interest costs[20]. - Research and development expenses for the period were ¥7,124,256.62, up from ¥6,148,646.52, indicating a focus on innovation despite financial losses[19]. Other Financial Metrics - The company experienced a 95.62% decrease in productive biological assets, amounting to a reduction of CNY 204,478,910.40, due to the elimination of some assets[9]. - The company reported a decrease in other income by 25,250,474.89, a reduction of 74.07% year-on-year, mainly due to decreased government subsidies[9]. - Deferred tax assets were adjusted to 68.57 million after a minor increase of 73.23 thousand[24]. - The retained earnings were adjusted to 1.02 billion, reflecting an increase of 72.22 thousand[24]. - The third quarter report was not audited[26].